FORTHCOMING PAPERS IN THE
BRITISH JOURNAL OF CANCER

Guest Editorial

Docetaxel (Taxotere™), a new anticancer drug with promising potential?
Verweij, J.

Experimental Oncology

Induction of esophageal and forestomach carcinomas in rats by reflux of duodenal contents
Miwatani, K., Segawa, M., Takano, Y., Matsumoto, H., Tahara, H., Yagi, M., Miyazaki, I., Hattori, T.

Photoimmunotherapy and biodistribution with an OC125-chlorin immunoonjugate in an in vivo murine ovarian cancer model
Goff, B.A., Hermanto, U., Rumbaugh, J., Blake, J., Bamberg, M., Hasan, T.

Reversion of multidrug resistance in the P-glycoprotein positive human pancreatic cell line (EPP85-181RDB) by introduction of a hammerhead ribozyme
Holm, P.S., Scanlon, K.J., Dietel, M.

Modulation of cisplatin cytotoxicity by sulfasalazine

Detection by DNA fingerprinting of somatic changes during the establishment of a new prostate cell line
van Helden, P.D., Wind, J.J.F., Hoof-van Helden, E.G., Bey, E., Cohen, R.

Control of human glioma growth, migration, and invasion in vitro by transforming growth factor-β1
Merzak, A., McCrea, S., Koocevčkour, S., Pilkington, J.G.

Photodynamic therapy using 5-aminolaevulinic acid for experimental pancreatic cancer – prolonged animal survival
Regula, J., Rati, B., Bedwell, J., MacRobert, A.T.J., Bown, S.G.

Effects of 4-hydroxytamoxifen and a novel pure antiestrogen (ICI 182780) on the clonogenic growth of human breast cancer cells in vitro
DeFriend, D.J., Anderson, E., Bell, J., Wilks, D.P., West, C.M.L., Mansel, R.E., Howell, A.

Purine and pyrimidine metabolism in human gliomas: relation to chromosomal aberrations
Bardout, V., Dutilhiaux, A.M., Delattre, J.Y., Vega, F., Poisson, M., Dutilhiaux, B., Ducq, C.

n-3 and n-6 fatty acid processing and growth effects in neoplastic and non-cancerous human mammary epithelial cell lines
Grammatikos, S.I., Subbioso, P.V., Victor, T.A., Miller, W.M.

Effects of inoculation site and Matrigel on growth and metastasis of human breast cancer cells
Bao, L., Matsumura, Y., Babin, D., Sun, Y., Tarin, D.

Enhancement of in vitro prostaglandin E₂-production by mouse fibrosarcoma cells after coculture with various anti tumour effector cells
Okada, F., Hosokawa, M., Hasegawa, J., Kuramitsu, Y., Nakai, K., Lan, Y., Lao, H., Kobayashi, H., Takeichi, N.

Proliferating cell nuclear antigen expression in non-cycling cells may be induced by growth factors in vivo
Hall, P.A., Coates, P.J., Goodlad, R.A., Hart, I.R., Lane, D.P.

Molecular genetic analysis of flow sorted ovarian tumour cells: improved detection of loss of heterozygosity

Contribution of host derived growth factors for in vivo growth of a transplantable murine mammary carcinoma
Davies, D.E., Farmer, S., White, J., Senior, P.V., Warnes, S.L., Alexander, P.

Clinical Oncology/Epidemiology

Progestogen use and decreased risk of breast cancer in a cohort study of premenopausal women with benign breast disease
Plu-Bureau, G., Le, M.G., Sitruk-Ware, R., Thalabard, J.C., Mauvais-Jarvis, P.

Prognostic value of cytosolic tyrosine kinase activity in 249 node-positive breast cancer patients

Progression and survival in prostatic adenocarcinoma. A comparison of clinical stage, Gleason stage, Gleason grade, S-phase fraction and DNA ploidy
Vesalainen, S., Nordling, S., Lipponen, P., Talja, M., Syrjänen, K.

Retention index of thallium-201 SPECT as an indicator of metastasis in adenocarcinoma of the lung

Association between syndecan-1 expression and clinical outcome in squamous cell carcinoma of the head and neck
Inki, P., Joensuu, H., Grönnmark, R., Kieler, P., Jalkanen, M.

Dannorubicin pharmacokinetics and the correlation with P-glycoprotein and response in patients with acute leukaemia
Gallietta, P., Bouty, J.-Y., Mo, D.D.F.

Improved prognosis of breast cancer since 1970 in Southeastern Netherlands
Nab, H.W., Hop, W.C.J., Crommelin, M.A., Kluck, H.M., Cobergh, J.-W.

Diagnosis of pancreatic adenocarcinoma by polymerase chain reaction from pancreatic secretions

Alpha-linolenic acid content of adipose breast tissue: a host determinant of the risk of early metastasis in breast cancer
Bougnoux, P., Koscielny, S., Chajés, V., Descamps, P., Couré, C., Calais, G.

Expression of tumour necrosis factor-α and its receptors in carcinoma of the breast
Pusztai, L., Closer, L.M., Cooper, K., Starkey, P.M., Lewis, C.E., McGee, J.O’D.

Overexpression of p53 and long-term survival in colon carcinoma
Auronen, A., Isola, J., Visakorpi, T., Koivula, T., Virtanen, S., Hakama, M.

Ablation of neoplasia by direct current
Taylor, T.Y., Pullam, B.R., Holt, S.

The effects of chemotherapy on morphology, cellular proliferation, apoptosis and oncoprotein expression in primary breast carcinoma

Frequent mutations of p53 gene in esophageal squamous cell carcinomas with and without human papillomavirus (HPV) involvement suggest the dominant role of environmental carcinogens in esophageal carcinogenesis
Chang, F., Syrjänen, S., Tervahauta, A., Kurvinen, K., Wang, L., Syrjänen, K.

Centralised treatment, entry to trials and survival
Stillier, C.A.

Management of ovarian cancer: referral to a multidisciplinary team matters
Junor, E.J., Hole, D.J., Gillis, C.R.

Reduced bone mineral density in men following chemotherapy for Hodgkin’s disease
Holmes, S.J., Whitehouse, R.W., Clark, S.T., Crowther, D.C., Adams, J.E., Shale, S.M.

p53 expression in normal and dysplastic bronchial epithelium and in lung carcinomas
Walker, C., Robertson, L.J., Mykowsk, M.W., Pendleton, N., Dixon, G.R.

Docetaxel (Taxotere™) a novel taxoid in the treatment of advanced colorectal carcinoma

Docetaxel (Taxotere™) in advanced gastric cancer: results of a phase II clinical trial

Docetaxel (Taxotere™) is active in non-small cell lung cancer: a phase II trial of the EORTC early clinical trials group (ECTG)
Cerny, T., Kaplan, S., Pavlidis, N., Schöffi, P., Eppelbaum, R., van Meerbeck, J., Wanders, J., Franklin, H.R., Kaye, S. for the ECTG (Early Clinical Trials Group of the EORTC)
LENATARON (4-hydroxyandrostenedione; 4-OHA) is a selective, fortnightly injectable aromatase inhibitor which marks an important development in the hormonal treatment of advanced breast cancer.

Up to now your main choice has been between anti-oestrogens and progestogens.

Now LENTARON offers a highly selective way of stopping tumour growth by inhibiting oestrogen synthesis. 1

Quite simply, LENTARON prevents the aromatase enzyme from completing the final step in the conversion of androgen precursors to oestrogen.

With its unique and selective mode of action, LENTARON is not only effective in preventing disease progression, but it also has a prolonged duration of response and a low incidence of side-effects. 1

So for patients who have relapsed on tamoxifen, offer LENTARON and you’ll offer renewed hope.

For a free LENTARON information pack, phone (0403) 272827 and ask for the Medical Information Department.
Notice to Contributors

The criteria for acceptance of manuscripts to be published in the British Journal of Cancer are originality and high scientific quality. Manuscripts are accepted on the understanding that they report unpublished work that is not under consideration for publication elsewhere, that all named authors have agreed to its submission and that if accepted it will not be published in the same form, in any language, without the consent of the Publishers. Papers should be in English. Authors whose mother-tongue is not English are urgently requested to have their manuscripts checked for linguistic correctness before submission. The Editors reserve the right to make literary corrections.

Papers reporting clinical studies should, where appropriate, contain a statement that they have been carried out with ethical committee approval. Single case studies are not usually acceptable. Papers disregarding the welfare of experimental animals will be rejected. Authors may find the UKCCCR Guidelines for the Welfare of Animals in Experimental Neoplasia helpful in this regard. These were published in the British Journal of Cancer (1988) 56, pp. 109–113. Alternatively, copies may be obtained from: UKCCCR, P.O. Box 123, Lincoln’s Inn Fields, London WC2A 3PX, UK.

Manuscripts should be sent in quaduplicate (original plus three copies) to the Editor-in-Chief, Dr Peter Twentyman. They should be typewritten, double-spaced with a wide margin and on one side of the paper only. They should be accompanied by a title page numbered as 1, bearing title, authors’ full names, affiliation and complete addresses, including postal (zip) codes; and a summary of not more than 200 words. A list of up to 6 keywords should follow the summary. The author and address to whom correspondence, proofs and reprint requests are to be sent should be clearly indicated.

A series of Editorials explaining the editorial policies and practices of the British Journal of Cancer was published in the Journal between November 1990 and March 1991. Composite reprints of these articles are available from the Editor-in-Chief on request.

Full papers should be divided into sections:
1. Introduction
2. Materials and methods
3. Results
4. Discussion
5. Acknowledgements and References.

Short Communications (~1500 words) should have the above section headings and a brief summary (~50 words).

Titles These are most important; authors should compose them with great care. They should combine brevity with clarity; the shorter the better, not exceeding 100 letters. Authors should submit their own running title, which must not exceed 50 letters.

References Only papers closely related to the author’s work should be quoted, and these should where possible be original papers rather than reviews. Exhaustive lists should be avoided. Citation of Conference Proceeding or Meeting Abstracts should also be avoided unless there is no other reference. References in the text should be made by giving the author’s surname, with the year of publication in brackets. When the reference is to a specific part of a book, the page number should also be cited. When reference is made to a work by 3 or more authors, the first name followed by et al. should be used on all occasions. If several papers by the same first author and from the same year are cited, a, b, c, etc. should be added after the year of publication.

It is the author’s responsibility to check the accuracy of all references before submitting a manuscript. References should be brought together at the end of the paper in alphabetical order, where titles of papers and all authors’ names should be given in full. Names of journals should be abbreviated as in the Index Medicus, but with full stops after abbreviations (and after authors’ initials), followed by the volume number and the initial and final page numbers, e.g.: McMANUS, M.J., DOMBROSKY, S.E., PIENKOWSKI, M.M. & WILSON, A.B. (1978). Successful transplantation of human benign breast tumours into the athymic nude mouse and demonstration of enhanced DNA synthesis by human placental lactogen. Cancer Res., 38, 2243–2248.

References to books and monographs should appear as in the following examples:

Abbreviations and units should follow the standards laid down in Units Symbols and Abbreviations published by the Royal Society of Medicine (third edition, 1977).

Drug names Generic names should be used.

Figures In the text Arabic numbers should be used and all illustrations should be specifically referred to in the text, e.g. (Figure 2). All illustrations should be submitted at about 1¼ times the intended final size and should be numbered as figures whether they are photographs, representational drawings or line diagrams and graphs. Copies of all Figures must accompany each of the 4 submitted copies of the manuscript.

Photographs and photomicrographs should be unmounted glossy prints, should not be retouched, and should be chosen to exclude technical artefacts. Magnification should be indicated by a line representing a defined length included within the photograph. Areas of key interest and/or critical reproduction should be indicated on a flimsy overlay attached to the photograph or on a photocopy. All annotation and lettering should be indicated in the same way, and preferably not included on the original print. Clearly contrasted and focussed prints are essential for adequate reproduction. Four originals of all photographs must be submitted. Photocopies of half-tone illustrations are generally unsuitable for refereeing purposes.

Full colour illustrations may be included within the text, at the discretion of the Editor-in-Chief. However, a charge will be made to the author to cover the extra costs incurred in originating and printing of colour illustrations. Authors will be advised of any such charges, which depend on the size and quantity of colour illustrations, prior to publication.

Line diagrams and graphs should be on separate sheets; they must be drawn with black ink on white paper or represent computer-generated output printed using laser or ink jet printers with appropriate line-smoothing facilities. Lettering on figures should be minimum and must not duplicate the legend. The use of symbols should be consistent within papers, and explanation of symbols should be included in the caption, not on the figure. Symbols should be sufficiently large that they will be clearly discernible following reduction.

Tables These should be as few as possible and should present only essential data. They should be typewritten on separate sheets, have a title or caption, and given Roman numbers.

Proofs Two marked copies of the proofs will be sent to the principal author and should be read carefully for errors. One corrected copy must be returned to the Editor-in-Chief within 3 days. Major alterations to the text cannot be accommodated.

Copyright Assignment The principal author must complete and return to the Publisher the Copyright Assignment Form enclosed with the proofs.

Offprints Twenty-five offprints will be supplied free of charge to the principal author. Additional offprints may be ordered on the form accompanying proofs. The charges are necessarily higher if orders are received after the issue has gone to press.

*Editorial correspondence (other than in direct response to a communication from one of the Subject Editors) should be addressed to Dr P.R. Twentyman, Editor-in-Chief, British Journal of Cancer, MRC Clinical Oncology and Radiotherapeutics Unit, Hills Road, Cambridge CB2 2QH, UK.